Studies methylation patterns to predict outcomes in hepatitis B liver failure
Looks at DNA methylation features in adults with hepatitis B-related acute-on-chronic liver failure.
Plain-language title generated from the registry record
Registry title: Analysis of Methylomic Features and Prognostic Risk Prediction in Patients With Hepatitis B-related Acute-on-chronic Liver Failure
Key facts
- Where
- Jinan, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with long-term hepatitis B infection, liver cirrhosis, or sudden liver failure on top of chronic liver disease caused by hepatitis B.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Disease stage
- Chronic hepatitis B (HBsAg positive for more than six months), hepatitis B-related liver cirrhosis, or hepatitis B-related acute-on-chronic liver failure with jaundice (serum total bilirubin ≥ 85 µmol/L) and a blood clotting problem (INR ≥ 1.5 or PTA < 40%).
- Biomarker or test result
- Persistent hepatitis B surface antigen (HBsAg) positive result for more than six months.
Main reasons for not taking part
- Co-infection with other hepatitis viruses
- History of liver cancer (hepatocellular carcinoma) or other cancers
- Autoimmune liver disease
- Not enough clinical data
Read by machine on 12 November 2026.
Where in China
- Qilu Hospital of Shandong UniversityJinan, ChinaContact: Yu-Chen FanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Qilu Hospital of Shandong University
- Trial code
- NCT07275554
- Record updated
- 10 December 2025
- Original description
This study aims to investigate the methylomic features of patients with hepatitis B-related acute-on-chronic liver failure and establish and validate a prognostic risk prediction classification model. The findings are of significant importance for guiding clinical practice and improving patient prognosis. Additionally, a methylomics-based classifier model for liver failure will be developed for disease prognosis analysis and clinical assessment, with the potential to enhance the diagnostic efficiency of liver failure.Read full original descriptionShow less
Analysis of Methylomic Features and Prognostic Risk Prediction in Patients With Hepatitis B-related Acute-on-chronic Liver Failure
This study aims to investigate the methylomic features of patients with hepatitis B-related acute-on-chronic liver failure and establish and validate a prognostic risk prediction classification model. The findings are of significant importance for guiding clinical practice and improving patient prognosis. Additionally, a methylomics-based classifier model for liver failure will be developed for disease prognosis analysis and clinical assessment, with the potential to enhance the diagnostic efficiency of liver failure.
Inclusion: Chronic hepatitis B was persistent hepatitis B surface antigen (HBsAg) seropositivity for more than six months; Hepatitis B-related liver cirrhosis was diagnosed based on histological examination, typical features on ultrasound or radiological imaging, endoscopic findings of portal hypertension, and clinical history; Hepatitis B-related acute-on-chronic liver failure meets the diagnostic criteria of the 2018 Asia-Pacific guidelines for the diagnosis and treatment of liver failure.Laboratory tests:Jaundice: Serum total bilirubin ≥ 85 µmol/L and coagulopathy [International Normalized Ratio (INR) ≥ 1.5 or Prothrombin Activity (PTA) < 40%].
Exclusion: co-infection with other hepatitis viruses; history of hepatocellular carcinoma or other malignancies; concomitant autoimmune liver disease; or insufficient clinical data.